Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 5
1948 2
1950 1
1951 1
1952 2
1953 1
1955 1
1956 3
1957 2
1958 1
1959 4
1960 1
1961 1
1962 1
1963 1
1964 1
1965 2
1967 1
1968 3
1969 4
1970 5
1971 2
1972 3
1973 2
1974 2
1975 4
1976 2
1977 3
1979 2
1984 1
1987 1
1988 2
1989 3
1990 4
1991 4
1992 3
1993 4
1994 4
1995 5
1996 6
1997 18
1998 8
1999 7
2000 24
2001 13
2002 30
2003 30
2004 32
2005 30
2006 18
2007 24
2008 25
2009 27
2010 30
2011 26
2012 38
2013 28
2014 29
2015 35
2016 48
2017 41
2018 46
2019 49
2020 44
2021 49
2022 51
2023 53
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

900 results

Results by year

Filters applied: . Clear all
Page 1
Pragmaticism in Cancer Clinical Trials.
Sankar K, Redman MW, Dragnev KH, Henick BS, Iams WT, Blanke CD, Herbst RS, Gray JE, Reckamp KL. Sankar K, et al. Among authors: herbst rs. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e100040. doi: 10.1200/EDBK_100040. Am Soc Clin Oncol Educ Book. 2024. PMID: 38771997 Review.
Building, Breaking, and Repairing Neuromuscular Synapses.
Herbst R, Huijbers MG, Oury J, Burden SJ. Herbst R, et al. Cold Spring Harb Perspect Biol. 2024 May 2;16(5):a041490. doi: 10.1101/cshperspect.a041490. Cold Spring Harb Perspect Biol. 2024. PMID: 38697654 Review.
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Bonanno L, Dómine M, Poole L, Bolanos A, Rukazenkov Y, Wu YL. Tsuboi M, et al. Among authors: herbst rs. Target Oncol. 2024 Mar;19(2):131-134. doi: 10.1007/s11523-024-01034-3. Epub 2024 Mar 11. Target Oncol. 2024. PMID: 38466534 Free PMC article.
Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers.
Lin DI, Huang RSP, Ladas I, Keller RB, Patel NR, Lakis S, Decker B, Janovitz T, Mata DA, Ross JS, Vergilio JA, Elvin JA, Herbst RS, Mack PC, Killian JK. Lin DI, et al. Among authors: herbst rs. Front Oncol. 2024 Feb 20;14:1328512. doi: 10.3389/fonc.2024.1328512. eCollection 2024. Front Oncol. 2024. PMID: 38444675 Free PMC article.
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA Jr, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. Brahmer JR, et al. Among authors: herbst rs. Eur J Cancer. 2024 Mar;199:113530. doi: 10.1016/j.ejca.2024.113530. Epub 2024 Jan 11. Eur J Cancer. 2024. PMID: 38295556 Free article.
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Galsky MD, Guan X, Rishipathak D, Rapaport AS, Shehata HM, Banchereau R, Yuen K, Varfolomeev E, Hu R, Han CJ, Li H, Liang Y, Vucic D, Wang L, Zhu J, Yu H, Herbst RH, Hajaj E, Kiner E, Bamias A, De Santis M, Davis ID, Arranz JÁ, Kikuchi E, Bernhard S, Williams P, Lee C, Mellman I, Sanjabi S, Johnston R, Black PC, Grande E, Mariathasan S. Galsky MD, et al. Among authors: herbst rh. Cell Rep Med. 2024 Feb 20;5(2):101393. doi: 10.1016/j.xcrm.2024.101393. Epub 2024 Jan 26. Cell Rep Med. 2024. PMID: 38280376 Free PMC article. Clinical Trial.
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst RS, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Parra ER, et al. Among authors: herbst rs. Clin Cancer Res. 2024 Apr 15;30(8):1655-1668. doi: 10.1158/1078-0432.CCR-23-0251. Clin Cancer Res. 2024. PMID: 38277235 Free PMC article.
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
Kochanek C, Gilde C, Zimmer L, Ugurel S, Meier F, Utikal J, Pföhler C, Herbst R, Haferkamp S, Welzel J, Dücker P, Leiter U, Weichenthal M, von Wasielewski I, Angela Y, Gutzmer R. Kochanek C, et al. Among authors: herbst r. Eur J Cancer. 2024 Feb;198:113508. doi: 10.1016/j.ejca.2023.113508. Epub 2023 Dec 28. Eur J Cancer. 2024. PMID: 38183763 Free article.
900 results